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Abstract: The object of this study is to evaluate the additional role ofRAS
mutation in detecting thyroid malignancy among BRAFV600E mutation-
negative nodules diagnosed as atypia of undetermined significance/follicu-
lar lesion of undetermined significance (AUS/FLUS) on cytology.
From December 2009 to December 2011, 202 BRAFV600E mutation-
negative thyroid nodules diagnosed as AUS/FLUS cytology in 201 patients
were included in this study. RAS mutation analysis was performed using
residual material from ultrasonography-guided fine needle aspiration (US-
FNA) cytology testing forK-RAS,N-RAS, andH-RAS codons 12/13 and 61
point mutations. The authors evaluated the association between RAS
mutation status and cytopathologic characteristics.
Of the 202 BRAFV600E mutation-negative thyroid nodules with AUS/
FLUS cytology, 4 were considered insufficient for mutation analysis. Of
the 198 thyroid nodules, 148 (74.7%) were confirmed as benign and 50
(25.3%) asmalignant. Thirty-one (15.7%) of the198 thyroidnoduleswere
positive for any RASmutation, 4 positive for K-RAS 12/13, 26 for N-RAS
61, and 1 positive for H-RAS 61. Seven (22.6%) of the RAS mutation
positive nodules were malignant, 1 with K-RAS 12/13, 6 with N-RAS 61.
Twenty-four (77.4%) of the 31 nodules positive forK-RAS 12/13 (N¼ 3),
N-RAS 61 (N¼ 20), orH-RAS 61 (N¼ 1) mutations were proven benign.
None of the 198 thyroid nodules were positive for K-RAS 61, N-RAS 12/
13, or H-RAS 12/13 mutations.
N-RAS 61 mutation is the most common mutation detected among, Hye Sun Lee, MS im, MD, PhD,
Jin Young Kwak, MD, PhD
investigation is anticipated to evaluate the true role of RAS mutation in
thyroid malignancy.
(Medicine 94(27):e1084)
Abbreviations: AUS/FLUS = atypia of undetermined significance/aspiration, US = ultrasonography.
INTRODUCTION
A lthough ultrasonography-guided fine needle aspiration(US-FNA) is considered the gold standard showing excel-
lent diagnostic performances in the diagnosis of thyroid
nodules,1–4 1 of the main flaws for this diagnostic method is
‘‘indeterminate’’ categories,5 including atypia of undetermined
significance/follicular lesion of undetermined significance
(AUS/FLUS), follicular neoplasm or suspicious for follicular
neoplasm, and suspicious for malignancy categories according
to the recently proposed Bethesda system for reporting thyroid
cytopathology.6 Considering the broad range of malignancy
rates among these categories, 5% to 75%, cytology results of
these categories warrant further invasive investigations such as
repeat US-FNA or diagnostic lobectomy,5–7 among which
approximately 66% will eventually be proven benign.8,9 Atypia
of undetermined significance/follicular lesion of undetermined
significance in particular, is a heterogeneous cytologic
category, including a broad disease spectrum, from patients
with air-drying artifact, low cellularity, or obscuring elements to
architectural or nuclear atypia.6 Malignancy risk for this
category has a broad range, reported from 6% to 42.1%,10–15
with management guidelines varying among reports or institu-
tions accordingly. At present, improving the accuracy of pre-
operative diagnosis for patients with this ambiguous cytologic
category is critical in patient management.
With the rapid evolution in molecular genetics, molecular
analysis has been reported and proposed as an effective adjunct
to cytologic evaluation in the differential diagnosis of thyroid
nodules, especially those with nondiagnostic or indeterminate
cytology.16–19 BRAFV600E mutation in particular, is present in
29% to 84% of papillary thyroid carcinoma (PTC),16,20–23
showing high specificity up to 100% and is potentially a useful
marker in predicting PTC in clinical practice. Several recent
studies have applied BRAFV600E mutation analysis in AUS/
FLUS nodules,11,24,25 and although this additional method was
helpful in stratifying nodules among this cytologic category,
approximately 39.7% to 70.8% of thyroid nodules negative for
BRAFV600E mutation proved to be malignant.11,24 RAS
mutations are the second most common genetic alterationrs,26,27 and the most common genetic
terminate thyroid nodules,28 but how it
lignancy among AUS/FLUS nodules,
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especially in those negative for BRAFV600E mutation, has not
been clarified.
In this study, we evaluated the usefulness of RASmutations
when used as an adjunct for definitive diagnosis of thyroid
nodules with AUS/FLUS cytology, which are negative for
BRAFV600E mutation.
METHODS
This retrospective study has been approved by the Institu-
tional Review Board (IRB) of Severance Hospital, Seoul, South
Korea. Neither patient approval nor informed consent was
required for review of medical records, cytology specimen,
or US images. Signed informed consent was obtained from
all patients before US-FNA or surgical procedures.
Patients
The Bethesda system has been used in reporting thyroid
cytopathology starting from December 2009 at our institution (a
referral center), and since then, this reporting system has been
consistently used. We performed a retrospective review of our
institutional database for all thyroid US-FNAs performed on
nodules measuring larger than 5mm during the period from
December 2009 to December 2011, and 13,456 US-FNAs had
been performed during this period. Among them, approximately
725 (5.4%) nodules had been diagnosed as AUS/FLUS on US-
FNA cytology. BRAFV600E mutation analysis was performed in
300 (41.4%) nodules, of which 262 (87.3%) nodules had negative
results. Thyroid nodules fulfilling the following inclusion criteria
were included in this study: nodules confirmed with surgery or
nodules that had been diagnosed as benign or malignancy on
follow-up US-FNA. Finally, 202 nodules in 201 patients were
included in this study. Mean age of the 201 patients was
58.5 11.8 years (range, 18–76 years). Mean size of the 202
thyroid nodules were 19.0 11.4mm (range, 5–61mm).
US and US-FNA Procedures
Real-time US and US-FNA procedures were performed by
1 of 14 board-certified radiologists (3 faculty, 11 fellows, 1–15
years of experience) using a 5- to 12MHz linear array transdu-
cer (iU22; Philips Medical Systems, Bothell, WA). Fine needle
aspiration was performed on thyroid nodules exhibiting suspi-
cious US features or at the largest mass among multiple benign-
appearing nodules.
Ultrasonography-guided fine needle aspiration was per-
formed with a 23-gauge needle connected to a 2mL disposable
syringe, using a freehand technique. Aspiration was performed
at least twice for each thyroid nodule, during which aspirated
material was expelled, smeared on glass slides, and placed
immediately in 95% ethanol for Papanicolaou staining. The
syringe used for aspiration was rinsed in normal saline for cell
block processing. One of 5 cytopathologists specializing in
thyroid cytopathology was involved in slide interpretation.
Cytopathologists were not on-site during procedures, and
additional immunohistochemical staining was performed on
the cytopathologist’s request. Since December 2009, cytology
reports of our institution were based on the Bethesda system for
reporting thyroid cytopathology.6
BRAFV600E Mutation Analysis
Yoon et alAdditional BRAFV600E mutation analysis was performed
when the referring clinicians requested them, or when it seemed
relevant to providing definitive diagnosis of thyroid nodules
2 | www.md-journal.comexhibiting suspicious US features. Aspiration was performed
once more for BRAFV600E mutation analysis after cytology
slide preparations, which were rinsed in 1mL of normal saline.
Dual priming oligonucleotide-based multiplex polymerase
chain reaction analysis (DPO-PCR) was used for BRAFV600E
mutation analysis from May 2008 to November 2011,29 and
real-time PCR was used from November 2011 to the current
date, according to the methods reported in prior studies.29,30
RAS Mutation Analysis
RAS mutation analysis was performed at N-RAS, H-RAS,
and K-RAS codon 12/13, and 61. Atypical cells of interest were
isolated from US-FNA cytology smear slides, and DNA was
extracted with QIAamp DNA mini kit (Qiagen, Germany) for
PCR. A specific primer for exon 2 for amplification of codon
12/13 mutations and a primer for exon 4 for amplification of
codon 61 mutations of the N-RAS,H-RAS, and K-RAS genes has
been prepared for PCR reaction. The PCR reaction medium
consisted of 2ml DNA, 1X Real HelixTM qPCR mixture
(Nanohelix, Korea), and optimized concentrations (10 nM) of
primers in a final volume of 20ml. Polymerase chain reaction
was performed under the following cycling conditions: prede-
naturation at 958C for 10 minutes, 45 cycles at 95 8C for 30
seconds, 608C for 30 seconds, and 728C for 30 seconds,
followed by final extension at 728C for 5 minutes.
For sequencing analysis, the PCR product was purified,
and single-strand reaction was carried out with each sequencing
primer sets and BigDye1 Terminator v3.1 Cycle Sequencing
Kit (ABI, CA). The DNA sequence was obtained with an ABI
PRISM 3730xl DNA Analyzer (ABI), and analyzed with the
Sequencing Analysis 5.1.1 software.
Data and Statistical Analysis
Histopathologic results from surgery and US-FNA were
used as the standard reference. Nodules with benign cytology
results on follow-up US-FNA, which had been followed
with US examinations performed at an interval of more than
12 months, also showing stable or decreased size were
considered benign. Nodules diagnosed as malignant on
US-FNA but had not undergone surgery were considered
malignant.
Independent 2-sample t-test was used in comparison of
continuous variables. Chi-square test or Fisher exact test was
used in comparison of categorical variables. All tests were 2-
sided, and P values of less than 0.05 were considered to have
statistical significance. Analyses were performed using SAS
(version 9.2, SAS Inc., Cary, NC).
RESULTS
Of the 202 BRAFV600E mutation-negative thyroid nodules
with AUS/FLUS cytology, 4 were found to have insufficient
amount of isolated nucleic acid for mutation analysis. The
remaining 198 thyroid nodules had undergone RAS mutation
analysis.Of the 198 thyroidnodules, 148 (74.7%)were confirmed
as benign, and 50 (25.3%) as malignant. Mean age of the patients
with malignant nodules did not show significant differences to
patients with benign nodules, 45.5 10.9 years to 49.1 11.8
years (P¼ 0.06). Mean size of the malignant nodules were
significantly smaller than benign ones, 12.2 10.3mm to
Medicine  Volume 94, Number 27, July 201516.2 11.3mm (P¼ 0.03).
Sixty-two patients with 62 (31.3%) thyroid nodules had
undergone surgery; 32 were confirmed as classical type (PTC),
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Correlation of K-RAS, N-RAS, H-RAS to Final Pathol-
ogy Results Among the 198 Thyroid Nodules With AUS/FLUS
Cytology and Negative BRAFV600E Mutation
Benign
(N¼ 148)
Malignant
(N¼ 50) Total
K-RAS 12/13
Negative 145 (98.0%) 49 (98.0%) 198 (98.0%)
Benign (129) PTC (35)
AH (9) FV-PTC (12)
LT (2) HCC, MI (1)
FA (3) Medullary (1)
HCA (2)
Positive 3 (2.0%) 1 (2.0%) 4 (2.0%)
Benign (3) PTMC (1)
G12V:2 G12V:1
G12D:1
K-RAS 61
Negative 148 (100.0%) 50 (100.0%) 198 (100.0%)
Positive 0 (0.0%) 0 (0.0%) 0 (0.0%)
N-RAS 12/13
Negative 148 (100.0%) 50 (100.0%) 198 (100.0%)
Positive 0 (0.0%) 0 (0.0%) 0 (0.0%)
N-RAS 61
Negative 128 (86.5%) 44 (88.0%) 172 (87.1%)
Benign (116) PTC (33)
AH (6) FV-PTC (9)
LT (2) HCC, MI (1)
FA (2) Medullary (1)
RAS mutation in BRAFV600E mutation negative AUS/FLUS nodules12 as PTC-follicular variant (FV-PTC), 9 as adenomatous
hyperplasia, 3 as follicular adenoma, 2 as lymphocytic thyroid-
itis, 1 asmedullary carcinoma, 2 as Hu¨rthle cell adenoma, and 1
as Hu¨rthle cell carcinoma, minimally invasive. One hundred
thirty-six (69.7%) nodules in 135 patients had undergone
follow-up US-FNA for diagnosis, and among them, 113 had
benign cytology and 3 had malignant results on follow-up US-
FNA. All the nodules with nondiagnostic (N¼ 6) and AUS/
FLUS (N¼ 14) cytology on follow-up US-FNA had shown
benign cytology results on third US-FNA.
Thirty-one (15.7%) of the 198 thyroid nodules were
positive for RAS mutation, of which 7 (22.6%) were proven
as malignant. Table 1 summarizes the RAS mutations to final
pathology of the thyroid nodules included in this study. Of
the 198 thyroid nodules, 4 were positive for K-RAS 12/13, 26
were positive for N-RAS 61, and 1 was positive for H-RAS 61.
Of the 4 nodules positive for K-RAS 12/13, 1 (25.0%) was
confirmed as papillary thyroid microcarcioma (PTMC)
(G12V). Of the 26 nodules positive for N-RAS 61, 6
(23.1%) were confirmed as malignant (2PTCs: Q61R,
1PTC: Q61K, 3 FV-PTC: Q61R). The single nodule positive
for H-RAS 61 was diagnosed as benign on US-FNA cytology.
Twenty-four (84.3%) of the nodules positive for K-RAS 12/13
(N¼ 3), N-RAS 61 (N¼ 20), or H-RAS 61 (N¼ 1) mutations
were proven benign. None of the 198 thyroid nodules
were positive for K-RAS 61, N-RAS 12/13, or H-RAS
12/13 mutations.
Based on the number of RAS mutations present in this
study, clinical features among thyroid nodules were analyzed
for nodules with any RAS mutation (Table 2). Nodule size was
significantly larger in nodules positive for N-RAS 61 mutation,
Medicine  Volume 94, Number 27, July 201520.2 14.5mm to 14.4 10.4mm (P¼ 0.01). Patient’s age and HCA (2)Positive 20 (13.5%) 6 (12.0%) 26 (12.9%)
Benign (16) PTC (3)
Q61R: 13 Q61R: 2,
Q61K: 3 Q61K: 1
AH (3) FV-PTC (3)
Q61R: 3 Q61R: 3
FA (1)
Q61R: 1
H-RAS 12/13
Negative 148 (100.0%) 50 (100.0%) 198 (100.0%)
Positive 0 (0.0%) 0 (0.0%) 0 (0.0%)
H-RAS 61
Negative 147 (99.3%) 50 (100.0%) 197 (99.5%)
Benign (131) PTC (36)
AH (9) FV-PTC (12)
LT (2) HCC, MI (1)
FA (3) Medullary (1)
HCA (2)
Positive 1 (0.7%) 0 (0.0%) 1 (0.5%)
Benign (1) -
Q61K:1
AH, adenomatous hyperplasia; AUS/FLUS, atypia of undetermined
significance/follicular lesion of undetermined significance; FA, follicu-
lar adenoma; FV, follicular variant; HCA, Hu¨rthle cell adenoma;sex did not show significant differences in thyroid nodules
positive for RAS mutation (all P> 0.05).
DISCUSSION
Indeterminate cytology, including AUS/FLUS, has been
considered problematic both to the patient and the clinician
because a definite diagnosis has not been reached, but still, both
the possibility of benignity or malignancy has been suggested
with the ambiguous cytologic result. Atypia of undetermined
significance/follicular lesion of undetermined significance
cytology in particular, has a recommended malignancy rate
of 15% to 30% by the Bethesda system,31 and although diag-
nostic lobectomy is recommended in patients with suspicious
features for malignancy, the majority of patients with AUS/
FLUS cytology is confirmed as benign for which surgery is
rather unnecessary. In effort to improve the accuracy of cyto-
logical diagnosis, molecular testing has been recently intro-
duced and BRAF, RAS, and RET/PTC mutations have been
popularly used and evaluated as an adjunctive tool in detecting
thyroid malignancy.32,33 BRAFV600E mutation is the most
common genetic alteration, which is highly specific for
PTC,5,16,34,35 has been proven as an useful adjunct to US-
FNA cytology in detecting malignancy among thyroid nodules
with indeterminate cytology with high positive predictive value
ranging from 87% to 100%.19,33 But, a considerable proportion
of BRAFV600E negative-nodules are proven as malignant, in
particular, malignancy rate of BRAFV600E negative-nodules
with AUS/FLUS cytology has been reported to be 39.7% to
62.7%.11,36,37 Malignancy rate of BRAFV600E mutation-nega-
tive nodules with AUS/FLUS cytology in this study was 25.3%,
slightly lower than the prior reports, but showing that a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.considerable amount of thyroid cancers are missed by
HCC, Hu¨rthle cell carcinoma; LT, lymphocytic thyroiditis; MI,
minimally invasive; FV-PTC PTC, papillary thyroid carcinoma;
PTMC, papillary thyroid microcarcioma.BRAFV600E mutation analysis alone.
In addition to BRAFV600E mutation, RAS mutation, the
second most common genetic alteration in thyroid cancer,38,39
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4 | www.md-journal.comhas been reported to be helpful in detecting follicular-patterned
thyroid tumors, especially FV-PTC among thyroid nodules of
indeterminate cytology.28,38–40 Results of a recent study show
that approximately 40.4% (23 of 57) BRAFV600E mutation-
negative nodules with AUS/FLUS cytology had RAS 61
mutations,28 among which 52.2% were surgically confirmed
as FV-PTC. The presence ofRASmutations suggests a possibility
of a broad spectrum of tumors from benign follicular adenoma to
follicular thyroid carcinoma, FV-PTC, anaplastic carcinoma and
poorly differentiated thyroid carcinoma,28,38,39,41,42 conditions
that arewell known to bedifficult to diagnosewith cytology alone
since they are often diagnosed as indeterminate with FNA, also
with the majority negative for BRAFV600E mutation. Most of the
studies evaluating the efficacy of RASmutation focus on thyroid
nodules with indeterminate cytology, including AUS/FLUS,
follicular neoplasm or suspicious for follicular neoplasm, and/
or suspicious formalignancy categories,28,38–40 and to our knowl-
edge, there are no studies published evaluating the usefulness of
RAS mutation among AUS/FLUS cytology category alone in
detecting thyroid cancers.
In this study, 15.7% (31 of 198) of the BRAFV600E
mutation-negative thyroid nodules with AUS/FLUS cytology
were positive for RAS mutation, of which 22.6% were proven
malignant. Also, 42.9% (3 out of 7 malignant nodules) were
confirmed as FV-PTC on surgery, the remaining 57.1% diag-
nosed as PTC. Both the proportion of the presence of RAS
mutation and the positive predictive value of RASmutation was
low, even when considering that this study had exclusively
included nodules with AUS/FLUS cytology. Similar to the
results of our study, in another study comparing the diagnostic
utility of BRAFV600E mutation to RAS and RET/PTC rearrange-
ments, the presence of RAS mutation in AUS/FLUS cytology
was 7.7%, whereas cancer risk was 0%.5 Unlike BRAFV600E
mutation, in which the presence of mutation almost always
predicts malignancy, the predictive value of RASmutation is not
as confirmative, since RAS mutations is also detected in benign
follicular adenomas, which obscures the performance of this
specific mutation, which must be considered when applying it
as an adjunctive diagnostic tool. As the prior study concluded,
based on the results of our study, we feel that the presence of
RAS mutation do not enhance the detection of thyroid cancers
BRAFV600E mutation-negative thyroid nodules with AUS/
FLUS cytology, even those of follicular patterned growth.
RASmutation consists of 3 highly homologous human RAS
genes, N-RAS, K-RAS, and H-RAS carrying mutations in codons
12, 13, and 61 have been described to be related to thyroid
tumorigenesis.38,39 The presence of different subtypes of RAS
mutation has been reported to be related to different clinico-
pathological outcomes, K-RAS 12/13 mutation showing signifi-
cantly lower carcinoma outcome compared with N-RAS 61 orH-
RAS 61 mutations.26 Our study showed similar results in that K-
RAS 12/13 mutation has a low malignancy rate, 75% (3 of 4) of
nodules with K-RAS 12/13 mutation were proven benign. N-RAS
61mutationwas themost commonmutation (83.9%, 26 of 31), as
with the results of previous reports,26,43 of which approximately
50% of nodules withN-RAS 61mutationwas proven as FV-PTC,
consistent to the prior report in that FV-PTC is the cancer subtype
mostly related to RAS 61 mutation.26,28,43 Only 1 benign thyroid
nodule had positive results for H-RAS 61 mutation, which is in
contrast with the prior report showing relatively high cancer rates
in nodules with H-RAS 61 mutation.28 In addition, malignancy
Medicine  Volume 94, Number 27, July 2015rate of N-RAS 61 mutation was 23.1% (6 of 26), lower than the
25.0% (1 of 4) for K-RAS 12/13, results which are in contrast to
the report in thatK-RASmutationwitholds lowermalignancy rate
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
26. Radkay LA, Chiosea SI, Seethala RR, et al. Thyroid nodules withthanN-RASmutation.26 The small number of nodules positive for
mutation may have affected the results, and as little has been
proven in the true characteristics of RAS mutation subclassifica-
tion, further studies including a large number of patients are
anticipated to evaluate the true utility of RAS mutation when
applied to lesion characterization or for risk stratification for
patient management.
There are several limitations to this study. First, this study
is of a retrospective design in which selection bias may have
occurred during patient inclusion. Second, only 31.2% of the
nodules included in this study had been confirmed with surgery,
whereas the remaining 68.8% had been diagnosed based on
cytology results. Third, subcategorization of AUS/FLUS
cytology has not been applied. Prevalence of RAS mutation
and predictive value for thyroid malignancy may differ among
subcategories of AUS/FLUS which has not been considered in
this study. Fourth, 1 of 5 cytopathologists was involved in
cytology interpretation, in which interobserver variability may
have existed. Fifth, direct sequencing has been used for
mutation analysis in this study, a method which has been known
to exclude mutations present in minor fractions of tumor cells,44
which may have affected our results.
In conclusion, N-RAS 61 mutation is the most common
mutation detected among BRAFV600E mutation-negative
nodules with AUS/FLUS cytology. RAS mutation has limited
value in predicting malignancy among BRAFV600E mutation-
negative thyroid nodules with AUS/FLUS cytology and further
investigation is anticipated to evaluate the true role of RAS
mutation in thyroid malignancy.
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